81 related articles for article (PubMed ID: 17651051)
21. Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 2004 Feb; 19(1):85-92. PubMed ID: 15068616
[TBL] [Abstract][Full Text] [Related]
22. Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
J Nucl Med; 2007 Feb; 48(2):269-76. PubMed ID: 17268025
[TBL] [Abstract][Full Text] [Related]
23. Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates.
Nakashima K; Watanabe H; Ono M
J Med Chem; 2023 Sep; 66(18):12812-12827. PubMed ID: 37721492
[TBL] [Abstract][Full Text] [Related]
24. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of a new bifunctional chelating agent for the preparation of radioimmunoconjugates.
Somayaji VV; Guay V; Peng Z; Sykes TR; Noujaim AA
Q J Nucl Med; 1995 Dec; 39(4):300-10. PubMed ID: 8624793
[TBL] [Abstract][Full Text] [Related]
27. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts.
Brekken C; Hjelstuen MH; Bruland ØS; de Lange Davies C
Anticancer Res; 2000; 20(5B):3513-9. PubMed ID: 11131655
[TBL] [Abstract][Full Text] [Related]
28. Preparation and evaluation of 211At labelled antineoplastic antibodies.
Walte A; Sriyapureddy SS; Korkmaz Z; Krull D; Bolte O; Hofmann M; Meyer GJ; Knapp WH
J Pharm Pharm Sci; 2007; 10(2):277s-285s. PubMed ID: 17718931
[TBL] [Abstract][Full Text] [Related]
29. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
[TBL] [Abstract][Full Text] [Related]
31. Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates.
Quadri SM; Vriesendorp HM
Q J Nucl Med; 1998 Dec; 42(4):250-61. PubMed ID: 9973840
[TBL] [Abstract][Full Text] [Related]
32. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates.
Davydova M; Dewaele Le Roi G; Adumeau P; Zeglis BM
J Vis Exp; 2019 Mar; (145):. PubMed ID: 30907883
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
Abbas Rizvi SM; Sarkar S; Goozee G; Allen BJ
Melanoma Res; 2000 Jun; 10(3):281-9. PubMed ID: 10890383
[TBL] [Abstract][Full Text] [Related]
36. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
[TBL] [Abstract][Full Text] [Related]
38. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
39. Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent.
Blend MJ; Stastny JJ; Swanson SM; Brechbiel MW
Cancer Biother Radiopharm; 2003 Jun; 18(3):355-63. PubMed ID: 12954122
[TBL] [Abstract][Full Text] [Related]
40. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
Press OW
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S19-26. PubMed ID: 9672771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
